BMS forms immuno-oncology collaboration with 10 US and EU cancer institutes
This article was originally published in Scrip
Bristol-Myers Squibb (BMS) formed the International Immuno-Oncology Network (II-ON) with 10 research centers in the US and EU as a global collaboration between industry and academia to broaden global scientific understanding of how the body's immune system can be harnessed to fight cancer.
You may also be interested in...
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.
When the US FDA approved Olumiant (baricitinib) for RA, it insisted on a lower dose because of fears of blood clots. Now that an NIH trial has shown that the product plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized COVID patients, Olumaint may get an emergency use authorization from FDA to treat a condition that itself causes blood clots. That doesn't mean the black box is going away; it's just a reminder that there is as much magic and mystery to medicine sometimes as there is science.
Private Company Edition: Neogene, Escient, ESCAPE, Resolution and Attralus raised a combined $320m in venture capital rounds. Also, large Recursion round could double the size of its pipeline, Korro Bio raised $91.5m and Flagship launched Generate Biomedicines.